Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL).

被引：4

作者：

Logue, Jennifer Marilyn

Krivenko, Gabriel S.

Larson, Victoria

Bachmeier, Christina A.

Chavez, Julio C.

Davila, Marco L.

Khimani, Farhad

Lazaryan, Aleksandr

Liu, Hien D.

Pinilla-Ibarz, Javier

Shah, Bijal D.

Dholaria, Bhagirathbhai R.

Jain, Michael D.

Locke, Frederick Lundry

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Univ S Florida, Tampa, FL USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[4] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA

[5] West Virginia Univ, Morgantown, WV USA

[6] Vanderbilt Univ, Med Ctr, Nashville, TN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.e14019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e14019

引用

页数：2

共 50 条

[31] Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.
Strati, Paolo
Leslie, Lori Ann
Shiraz, Parveen
Budde, L. Elizabeth
Oluwole, Olalekan O.
Ulrickson, Matthew
Ramakrishnan, Aravind
Sun, Jennifer
Shen, Rhine
Kanska, Justyna
McCroskery, Peter
Dong, Jinghui
Schupp, Marco Andreas
Xu, Hairong
Patel, Krish
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[32] Product attributes of axicabtagene ciloleucel (axi-cel) that associate differentially with efficacy and toxicity in second-line large B-cell lymphoma
Filosto, Simone
Vardhanabhuti, Saran
Canales, Miguel
Poire, Xavier
Lekakis, Lazaros J.
de Vos, Sven
Portell, Craig A.
Wang, Zixing
To, Christina
Cheng, Paul
Chou, Justin
Bot, Adrian
Shen, Rhine
Westin, Jason R.
CANCER RESEARCH, 2022, 82 (12)
[33] Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
Cook, Michael Roderick
Shouval, Roni
Perales, Miguel-Angel
Bezerra, Evandro
Niu, Alex
Dahiya, Saurabh
Nastoupil, Loretta J.
Jacobson, Caron A.
Budde, L. Elizabeth
Olson, Amanda L.
Logan, Brent R.
Hu, Zhen-Huan
Wang, Hai-Lin
Luo, Zhong-Cheng
Kim, Jenny J.
Smith, Harry W.
Lee, Andrew
Sun, Fang
Pasquini, Marcelo
Locke, Frederick L.
BLOOD, 2023, 142
[34] A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel [Axi-Cel]) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)
Neelapu, Sattva S.
Locke, Frederick L.
Bartlett, Nancy L.
Lekakis, Lazaros J.
Reagan, Patrick M.
Miklos, David B.
Jacobson, Caron A.
Braunschweig, Ira
Oluwole, Olalekan O.
Siddiqi, Tanya
Lin, Yi
Crump, Michael
Kuruvilla, John
Van Den Neste, Eric
Farooq, Umar
Navale, Lynn
DePuy, Venita
Kim, Jenny J.
Gisselbrecht, Christian
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S232 - S232
[35] A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel; Axi-Cel) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)
Neelapu, Sattva S.
Locke, Frederick L.
Bartlett, Nancy L.
Lekakis, Lazaros J.
Reagan, Patrick
Miklos, David B.
Jacobson, Caron A.
Braunschweig, Ira
Oluwole, Olalekan
Siddiqi, Tanya
Lin, Yi
Crump, Michael
Kuruvilla, John
Van den Neste, Erin
Farooq, Umar
Navale, Lynn
DePuy, Venita
Kim, Jenny
Gisselbrecht, Christian
MOLECULAR THERAPY, 2020, 28 (04) : 575 - 576
[36] Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)
Jacobson, Caron
Locke, Frederick L.
Ghobadi, Armin
Miklos, David B.
Lekakis, Lazaros J.
Oluwole, Olalekan O.
Lin, Yi
Braunschweig, Ira
Hill, Brian T.
Timmerman, John M.
Deol, Abhinav
Reagan, Patrick M.
Stiff, Patrick J.
Flinn, Ian W.
Farooq, Umar
Goy, Andre H.
McSweeney, Peter A.
Munoz, Javier
Siddiqi, Tanya
Rossi, John M.
Bot, Adrian
Zheng, Lianqing
Vezan, Remus
Bashir, Zahid
Kim, Jenny J.
Chu, Rong
Neelapu, Sattva S.
BLOOD, 2020, 136
[37] Axicabtagene Ciloleucel (Axi-Cel) In Patients With Refractory Large B Cell Lymphoma: Long-Term Safety and Efficacy of ZUMA-1
Neelapu, S. S.
Ghobadi, A.
Jacobson, C. A.
Miklos, D. B.
Lekakis, L. J.
Oluwole, O. O.
Lin, Y.
Braunschweig, I.
Hill, B. T.
Timmerman, J. M.
Deol, A.
Reagan, P. M.
Stiff, P.
Flinn, I. W.
Farooq, U.
Goy, A.
McSweeney, P. A.
Munoz, J.
Siddiqi, T.
Chavez, J. C.
Herrera, A. F.
Xue, A.
Jiang, Y.
Bot, A.
Rossi, J. M.
Kim, J. J.
Go, W. Y.
Locke, F. L.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 26 - 27
[38] Eltrombopag Stimulation for Neutrophil and Platelet Recovery Following Axicabtagene Ciloleucel (axi-cel) Therapy in Lymphoma
Wesson, William
Nelson, Maggie
Mushtaq, Muhammad
Bansal, Rajat
Kribs, Robert
Singh, Anurag K.
Hoffmann, Marc
Tun, Aung M.
Abdallah, Al-Ola
Abdelhakim, Haitham
Abhyankar, Sunil H.
McGuirk, Joseph P.
Shune, Leyla O.
Ahmed, Nausheen
BLOOD, 2022, 140 : 12757 - 12759
[39] Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.
Locke, Frederick Lundry
Ghobadi, Armin
Jacobson, Caron A.
Jacobsen, Eric D.
Miklos, David Bernard
Lekakis, Lazaros J.
Braunschweig, Ira
Oluwole, Olalekan O.
Lin, Yi
Siddiqi, Tanya
Deol, Abhinav
Reagan, Patrick Michael
Farooq, Umar
Bot, Adrian
Jiang, Yizhou
Rossi, John M.
Xue, Allen
Go, William Y.
Neelapu, Sattva Swarup
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[40] Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the US Lymphoma CAR-T Consortium.
Spiegel, Jay Y.
Dahiya, Saurabh
Jain, Michael D.
Nastoupil, Loretta J.
Ghobadi, Armin
Lin, Yi
Lunning, Matthew Alexander
Reagan, Patrick Michael
McGuirk, Joseph
Deol, Abhinav
Munoz, Javier
Locke, Frederick Lundry
Neelapu, Sattva Swarup
Tamaresis, John S.
Rapoport, Aaron
Miklos, David Bernard
Hill, Brian Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →